<DOC>
	<DOCNO>NCT02122081</DOCNO>
	<brief_summary>This pilot clinical trial aim assess feasibility tolerability use LINAC base `` organ-sparing marrow-targeted irradiation '' condition patient high-risk hematological malignancy otherwise ineligible undergo myeloablative Total body irradiation ( TBI ) -based condition prior allogeneic stem cell transplant . The target patient population ALL , AML , MDS either elderly ( &gt; 50 year age ) healthy , young patient worse medical comorbidities ( HCT-Specific Comorbidity Index Score ( HCT-CI ) &gt; 4 ) . The goal patient benefit potentially efficacious myeloablative radiation base condition approach without side effect associate TBI .</brief_summary>
	<brief_title>Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant Treating Patients With High-Risk Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess feasibility tolerability OSMI base hematopoietic stem cell transplant ( HSCT ) define transplant-related mortality ( TRM ) day 30 well rate grade II/III organ toxicity ( defined Bearman Regimen-Related Toxicities Scale ) attributable condition occur within 30 day . SECONDARY OBJECTIVES : I . Day 100 transplant-related mortality ( TRM ) . II . Donor chimerism assessment day 100 ( assess failure engraftment rate ) . III . Incidence acute graft-versus-host disease ( aGVHD ) day 100 . IV . Incidence chronic GVHD one year . V. Cumulative incidence grade II organ toxicity day 100 . VI . Rate kinetics hematopoietic recovery . VII . Incidence graft failure ( primary secondary ) . VIII . Rate infectious complication . IX . Cumulative incidence relapse , overall survival , progression-free survival 1 year . OUTLINE : CONDITIONING REGIMEN : Patients undergo organ-sparing marrow irradiation twice daily ( BID ) day -6 -4 receive cyclophosphamide intravenously ( IV ) 1-2 hour every 24 hour day -3 -2 . Patients unrelated donor also receive anti-thymocyte globulin every 24 hour day -4 -2 . GVHD PROPHYLAXIS : Patients receive tacrolimus IV orally ( PO ) begin day -1 continue least 6 month methotrexate IV day 1 , 3 , 6 , 11 . TRANSPLANT : Patients undergo allogeneic peripheral blood progenitor cell bone marrow transplant day 0 . After completion study treatment , patient follow weekly 12 week , day 100 , 6 12 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Patients diagnosis acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , myelodysplastic syndrome ( MDS ) few 10 % myeloblast lymphoblasts bone marrow blast peripheral blood morphologic analysis perform within 30 day start condition regimen ; remission bone marrow available beyond 30 day new bone marrow evaluation require assess remission status The diagnosis AML , ALL , MDS base World Health Organization ( WHO ) criteria Pretransplant bone marrow sample must evaluable assessment remission status ( i.e . aspirate smear contain particle and/or evaluable bone marrow core biopsy ) Patients leukemia infiltration central nervous system ( CNS ) eligible cerebrospinal fluid ( CSF ) cytospin negative myeloblast lymphoblast time enrollment If patient intraabdominal chloroma presentation , partial response complete response treatment ( size reduction chloroma marrow blast &lt; 10 % ) , patient eligible ; however chloroma must include part treatment target For patient receive treatment AML , MDS ALL prior transplantation : Interval start cycle conventional cytotoxic chemotherapy start condition regimen must least 30 day Interval complete treatment hypomethylating agent noncytotoxic chemotherapy start condition regimen must least 10 day Hematopoietic Cell TransplantationSpecific Comorbidity Index score ( HCTCI ) = &lt; 4 patient Cohort 1 &gt; 4 Cohort 2 Patient must able lie still full body cast 45 minute Must suitable donor define sibling match 5/6 6/6 antigen ( human leukocyte antigen [ HLA ] A , B , DRB1 ) unrelated volunteer match 7/8 8/8 HLA allele ( HLAA , B , C , DRB1 ) Signed informed consent DONOR : `` High resolution '' type HLAA , B , C DRB1 alleles Single antigen mismatch sibling single allele mismatch volunteer unrelated donor acceptable Donors must &gt; = 17 year age Circulating peripheral blood myeloblast lymphoblasts morphologic analysis time last treatment time enrollment Prior allograft prior autograft Active CNS disease identify positive CSF cytospin time enrollment Karnofsky performance score &lt; 70 Symptomatic uncontrolled coronary artery disease ejection fraction &lt; 40 % Total bilirubin &gt; = 2 x upper limit normal Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; = 3 x upper limit normal Diffusion capacity lung carbon monoxide ( DLCO ) &lt; 40 % Forced expiratory volume one second ( FEV1 ) &lt; 50 % ( correct hemoglobin ) Receiving supplementary continuous oxygen Creatinine clearance &lt; 50 mL/min/1.73m^2 Patients active uncontrolled bacterial , viral fungal infection ( undergo appropriate treatment progression clinical symptom ) Patients seropositive human immunodeficiency virus ( HIV ) Females pregnant breastfeed Fertile men woman unwilling use contraceptive technique 12 month follow treatment Patients prior radiation 20 % bone marrow contain area area exceed 2000 cGy DONOR : Donors exclude identical twin recipient Females pregnant ( positive serum beta human chorionic gonadotropin beta [ Î² HCG ] ) uninterruptible breastfeed HIV seropositive Donors receive experimental therapy investigational agent unless approve protocol chair</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>